Form 4: Septerna CPO Samira Shaikhly Executes Stock Option Sale

Chief People Officer Samira Shaikhly exercised options to acquire and subsequently sold 6,250 shares of Septerna, Inc. common stock.

Summary

• Samira Shaikhly, Chief People Officer of Septerna, Inc., exercised stock options for 6,250 shares at a strike price of $11.70.
• Following the exercise, the reporting person sold the 6,250 shares at a weighted average price of $35.0759 per share.
• The transactions were executed on June 12, 2026, pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.
• Post-transaction, the reporting person retains 793 shares of common stock and 23,750 unexercised stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-arranged 10b5-1 plan and represents standard executive financial management.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information.
• The sale price of approximately $35.08 represents a significant gain over the $11.70 exercise price.

Negatives

• The transaction results in a reduction of the executive's direct equity stake in the company.

Risks

• Future share price volatility may impact the value of remaining unexercised options held by the executive.

Future Outlook

No forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice in the biotechnology sector, often used by executives for liquidity and diversification rather than signaling a lack of confidence in the company's pipeline.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for corporate officers to avoid potential insider trading allegations.
• The volume of shares sold is relatively small compared to total outstanding shares, typical for executive compensation liquidity events.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and executed at market prices.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Septerna, SEPN, Insider Trading, Form 4, Stock Options, Biotech